Type Private Founded 1989 | Industry Biomedical Engineering | |
Headquarters Mississauga, Ontario, Canada Key people George Q. W. Yeh, President Products Biopharmaceuticals
Immunodiagnostic Products | ||
Anogen is the trade name of Yes Biotech Laboratories Ltd., a Canadian biopharmaceutical company based in Mississauga, Ontario. Founded in 1989, Anogen-Yes Biotech specializes in developing and manufacturing monoclonal antibodies, recombinant proteins, synthetic bioactive peptides, and Enzyme linked immunosorbent assay (ELISA) kits for research as well as diagnostic and therapeutic use. It is also committed to seeking medical treatment of cancer, autoimmune, inflammatory and cardiovascular diseases by developing antibody-based biopharmaceuticals. It has an office in Orlando, United States, and two research facilities in China, one in Xuzhou and another in Shanghai.
Contents
Psoriasis
The company has developed a proprietary technology for topical antibody treatment of various skin conditions. In early 1999, Abcream, the topical treatment of psoriasis and eczema with anti-Interleukin 8 neutralizing antibody, completed a double-blinded, placebo controlled Phase II/III clinical trials. In these studies, 49% to 53.8% of patients achieved a > 60% improvement and 12.9% to 15.3% of patients achieved a > 90% improvement in Psoriasis Area Severity Index (PASI) score after a six-week treatment cycle with Abcream. In 2002, 1452 patients with psoriasis vulgaris had completed for the Phase IV clinical trail. Of 61.91% patients achieved a > 60% improvement and 17.85% of patients achieved a > 90% improvement in PASI score after an eight-week treatment cycle with Abcream. No significant side effect of any kind was observed during and after the treatment. Abcream (registered as Enboke in China) has been approved by State Food and Drug Administration (SFDA) of China for the treatment of psoriasis and eczema in 2003.
Cardiovascular diseases
It has also developed a monoclonal antibody (R813) to human platelet surface glycoprotein IIIa. The Phase I clinical trial has been completed that this antibody effectively inhibits the aggregation of human platelet with less hemorrhagic risk. Both in vitro and in vivo studies suggest its therapeutic potential for treatment of cardiovascular diseases.
Alzheimer's disease
Three anti-Aβ42 monoclonal antibodies (Xuzhou 1, 2 and 3) have been developed in 2011 for early detection and treatment of Alzheimer’s Disease. The clinical trials are planned to be completed within two years.
Inflammatory diseases
The company has begun to develop anti-inflammatory therapy with humanized neutralizing monoclonal antibodies to chemokines.